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Abstract 
Rubella is a vaccine-preventable viral infection, its aetiologic agent; rubella virus was identified as human teratogen 
capable of causing a spectrum of birth defects described as congenital rubella syndrome (CRS).  Despite the availability 
of safe and effective vaccines, significant proportion of the population remains susceptible to rubella infection in 
developing countries.  More significantly, such developing countries including Nigeria have not demonstrated 
adequate commitment to preventive vaccination; a panacea for intervention.  Consequently, this study was designed to 
determine the prevalence of anti-rubella IgG among pregnant women to ascertain the proportion of susceptible 
population.  A total of 273 consenting rubella vaccine naïve antenatal clinic attendees aged 15-42 years (Median age = 28 
years) were randomly selected and their sera analyzed for qualitative and quantitative anti-rubella IgG detection.  
Overall, 244/273 (89.4%) pregnant women enrolled in this study had protective level (Titre = >10 IU/mL) of anti-rubella 
IgG (Median Titre = 165 IU/mL; Range = <10 - >250 IU/mL), while, 29/273 (10.6%) of the study population lack 
protective antibody titre ( OD = <10 IU/mL).  Results confirm previous reports of exposure, infection, and continuous 
circulation of rubella virus in Nigeria.  It emphasizes the need for improved and continuous surveillance for rubella 
and CRS cases, prompt vaccination of vulnerable populations, and evaluation of health policies to achieve 
immunization and ultimately ensure control/elimination of rubella virus in Nigeria and beyond. 
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INTRODUCTION 
Rubella is a vaccine-preventable viral infection of 
the skin and lymph nodes often culminating in a 
mild rash.  The aetiologic agent is a positive sense 
single-stranded RNA rubella virus in the family 
Togaviridae [1, 2].  The virus has been identified as 
a human teratogen capable of causing a spectrum 
of birth defects often collectively referred to as 
congenital rubella syndrome [3, 4, 5] or death [6, 
7] of a developing foetus, especially if the viral 
infection is acquired in the early months, that is 
first trimester of pregnancy [2, 8, 9, 10].  
 
In spite of the availability of a safe and effective 
vaccine against rubella, an estimated over 100,000 
infants are born with congenital rubella syndrome 
annually [6, 11, 12].  Additionally, approximately 
3 to 23% of adults remain susceptible to rubella 
virus infection in various countries and areas, 
although studies have shown that a large 
proportion of unimmunized populations in areas 
where rubella is endemic are infected and become 
seropositive before puberty [13, 14, 15, 16]. 
 
Dwyer et al., (2001) noted that about 10-25% of 
non-immunized women of childbearing age are  
 
 
susceptible to rubella virus infection [17].  
Furthermore, studies have shown that 80-90% of 
babies born to women infected with rubella virus 
during the first trimester of gestation experience 
birth defects [9, 18].  Humans are the only known 
reservoir for rubella virus; hence, its maintenance 
requires continuous access to a susceptible 
population.  Equally, elimination of rubella and 
CRS with an effective vaccination program in 
some countries [19] is an evidence of achievable 
intervention plan for rubella virus and the 
disease.  
 
Despite the reality of preventive rubella vaccine, 
routine screening and preventive vaccination 
against rubella virus for women and children 
have not been incorporated into the antenatal care 
and National Program on Immunization (NPI) in 
Nigeria.  Also, rubella infection and CRS are not 
reportable diseases in the country.  Therefore, to 
achieve intervention in Nigeria and beyond, there 
is the need to assess current situation of rubella 
infection especially among at risk population.  
Such information is essential to demonstrate the 
need for government to support preventive 
vaccination, especially among women of 
childbearing age, and surveillance for CRS to 
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facilitate prompt intervention.  Therefore, to 
achieve the aforementioned, this study was 
designed to determine the prevalence of anti-
rubella IgG among pregnant women in order to 
ascertain the proportion of susceptible 
population.   
 
MATERIALS AND METHODS 
STUDY LOCATION 
This study was carried out among pregnant 
women attending Ade-Oyo Maternity Hospital in 
Ibadan, south western, Nigeria. The hospital is 
located in a densely populated centre of the city 
and serves pregnant women of varied educational 
status from different parts of the city. The ante-
natal clinic records an average of 380 + 20 new 
patients per week. 
ENROLMENT OF THE STUDY POPULATION 
Participants for this study were enrolled in July, 
2010.  After approval was obtained from the 
Hospital Management Board, each prospective 
participant was counselled, and only consenting 
clinic attendees were enrolled for the study. 
During the enrolment period, the ante-natal clinic 
was visited five times.  Blood samples were 
collected from a total of 273 consenting pregnant 
women (Median age = 28 years; Range = 15 - 42 
years) at the point of registration for the ante-
natal clinic.   The participants were mostly women 
of low educational status, thus could not provide 
any proof or record of rubella vaccination.  
Rubella vaccines are currently available in Nigeria 
at a cost, thus limited to the elites who appreciate 
the importance of preventive vaccination.  
 
SAMPLE COLLECTION, PREPARATION AND 
STORAGE 
About 5 millilitres of blood specimen was 
collected by venepuncture from each consenting 
pregnant woman into a sterile container free of 
anticoagulants or preservatives.  Each specimen 
was labelled with the date of collection and 
laboratory identity number.  Samples were 
transported to the laboratory immediately in a 
cold box with frozen ice packs to achieve 
condition of about 4-8oC. Serum samples were 
separated by low-speed centrifugation at 500 x g 
for 5 minutes, or direct removal of the serum 
using a sterile disposable pipette after retraction 
of the clot. The serum was transferred into 
labelled sterile cryovials and stored at -20oC until 
ready for analysis.  
 
LABORATORY ANALYSIS 
The laboratory analysis was carried out in the 
Department of Virology, College of Medicine, 
University College Hospital, Ibadan. The samples 
were analyzed for qualitative and quantitative 
detection of anti-rubella IgG antibody using 
DIA.PRO Diagnostic Bioprobes s.r.l. (Sede legale: 
Via Lucio Giunio Columella, 31-20128-Milano) 
Enzyme Immunoassay in accordance with the 
manufacturer’s description. The test kit has 
diagnostic sensitivity and specificity performance 
of >98%. 
STATISTICAL ANALYSIS 
Demographic features of the study population 
were described.  Also, results of the study were 
analyzed using the statistical package for the 
social sciences (SPSS) version 15.0 windows, and 
p-value <0.05 was considered statistically 
significant. 
 
RESULTS 
Overall, 244/273 (89.4%) pregnant women 
enrolled in this study had protective level (Titre = 
>10 IU/mL) of anti-rubella IgG (Median Titre = 
165 IU/mL; Range = <10 - >250 IU/mL), while, 
29/273 (10.6%) of the study population lack 
protective antibody titre (OD = <10 IU/mL).  
Nine out of the twenty-nine (31.0%) women in the 
later category had no detectable anti-rubella IgG 
antibody (OD < 0 IU/mL.  Analysis by age shows 
highest and lowest rates of seropositivity in age 
groups >40 and 31-40 years respectively (Table 1).  
However, no statistically significant difference 
(p=0.906) was recorded in the rates of 
seropositivity to rubella virus infection by age. 
 
DISCUSSION 
Previous studies [20, 21, 22, 23, 24] have reported 
varied prevalence rates of anti-rubella IgG among 
Nigerian population including pregnant women.  
More significantly, in 2002 Bukbuk et al., [25] in a 
study among non-immunized pregnant women in 
Maiduguri, north eastern Nigeria reported 54.1% 
prevalence of rubella-specific IgG antibody.  
Consequently, detection of anti-rubella IgG in 
89.4% of pregnant women without history of 
rubella vaccination in this study corroborates 
findings from previous studies in the country [20, 
21, 22, 23, 24, 25].  Furthermore, detection of anti-
rubella IgG among rubella pregnant women 
without vaccine history is an indication of 
previous exposure and subclinical or clinical 
infection by rubella virus. Therefore, this confirms 
continuous circulation of rubella virus in a 
country where preventive rubella vaccine is only 
available for the informed adult population at a 
cost.  Additionally, it confirms earlier reports [24, 
26, 27] that rubella virus may have been 
circulating continuously in Nigeria but for 
paucity of data on its burden.   
 
  
 
  
TABLE 1: RUBELLA IgG ANTIBODY AMONG PREGNANT WOMEN OF DIFFERENT AGE GROUPS ATTENDING 
ANTE-NATAL CLINIC IN IBADAN, NIGERIA 
 
 
AGE (YEAR) NUMBER TESTED (%) NUMBER POSITIVE (%) NUMBER NEGATIVE 
(%) 
< 20 30 (11.0) 27 (90) 3 (10) 
21-30 170 (62.3) 152 (89.4) 18 (10.6) 
31-40 69 (25.3) 61 (88.4) 8 (11.6) 
> 40 4 (1.5) 4 (100.0) 0 (0) 
TOTAL 273 (100) 244 (89.4) 29 (10.6) 
 
Highest rates of seropositivity to rubella observed 
among age group >40 years supports earlier 
suggestion that longer period and probably 
higher frequency of childbearing and nursing 
experienced in such age group may predispose 
them to greater risk of exposure and infection.  
Lack of protective rubella IgG antibody in 29/273 
[10.6%] of the study population and more 
significantly lack of detectable antibody in 9 out 
of the 29 women suggest existence of susceptible 
population for rubella virus maintenance in the 
community.  This finding confirms earlier reports 
[26, 28] that despite the development and 
administration of effective vaccines for prevention 
and control of rubella virus infection since 1969 
and prevention or elimination of the causative 
agent in many developed countries, cases of 
rubella virus infection and CRS are still being 
reported among diverse groups in Nigeria. 
 
However, since humans are the only known 
reservoir for rubella virus, maintenance of rubella 
requires continuous access to a susceptible 
population. Therefore, an enhanced 
immunization programme aimed at ensuring high 
level of herd immunity would facilitate the 
control of rubella epidemics [29].  Furthermore, 
findings from this and previous studies in the 
country indicate that Nigeria has in its hands, an 
opportunity to eliminate the virus since the 
burden is low and the definite susceptible 
population is defined.   
 
Rubella naive individuals are susceptible to 
infection, thus constitute risk of transmission and 
maintenance of a vaccine-preventable virus 
infection in the community and the world at large. 
Prevention or elimination of rubella virus 
infection has been achieved in many developed 
countries with the introduction of preventive 
vaccine.  Therefore, to facilitate prompt and 
effective virus elimination in the country, 
immediate introduction of preventive rubella 
vaccination to susceptible population is essential.  
 
In conclusion, results of the study emphasize the 
need for establishment of an improved and 
continuous surveillance network for rubella 
infection and CRS cases; prompt vaccination of 
vulnerable population and periodic evaluation of 
health policies to guarantee immunization.  Thus, 
to facilitate prompt elimination of rubella we 
recommend the establishment of health policy 
that promotes: (a) free vaccination programmes 
for children and adults of childbearing age (b) 
evaluation of available vaccines to ascertain their 
potency prior recommendation for vaccination (c) 
review of antibody response in randomly selected 
individuals post vaccination, and (d) rubella virus 
and CRS surveillance.   
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